Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
3.150
-0.050 (-1.56%)
Jan 14, 2025, 4:00 PM EST - Market closed
Atea Pharmaceuticals Employees
Atea Pharmaceuticals had 75 employees as of December 31, 2023. The number of employees increased by 5 or 7.14% compared to the previous year.
Employees
75
Change (1Y)
5
Growth (1Y)
7.14%
Revenue / Employee
n/a
Profits / Employee
-$2,320,080
Market Cap
266.06M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 75 | 5 | 7.14% |
Dec 31, 2022 | 70 | 11 | 18.64% |
Dec 31, 2021 | 59 | 20 | 51.28% |
Dec 31, 2020 | 39 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
AVIR News
- 6 days ago - Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 27 days ago - Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process - Business Wire
- 4 weeks ago - Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships - GlobeNewsWire
- 5 weeks ago - After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study - Benzinga
- 5 weeks ago - Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV) - GlobeNewsWire
- 7 weeks ago - Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript - Seeking Alpha